GH Research (NASDAQ:GHRS) Stock Price Down 1% – Time to Sell?

GH Research PLC (NASDAQ:GHRS) dropped 1% during mid-day trading on Thursday . The stock traded as low as $7.93 and last traded at $8.25. Approximately 38,773 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 79,565 shares. The stock had previously closed at $8.33.

Wall Street Analyst Weigh In

GHRS has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Stock Performance

The firm has a market cap of $422.99 million, a PE ratio of -12.31 and a beta of 0.79. The firm’s 50 day moving average price is $8.15 and its two-hundred day moving average price is $10.57.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. On average, analysts forecast that GH Research PLC will post -0.89 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. boosted its holdings in GH Research PLC (NASDAQ:GHRS) by 11.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the quarter. RA Capital Management L.P. owned about 12.02% of GH Research worth $66,643,000 at the end of the most recent quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).